On May 14, 2020 CellProtect Nordic Pharmaceuticals reported that results from the first-in-human study ACP-001 was made public at the 2020 EHA (Free EHA Whitepaper) meeting (Press release, CellProtect Nordic Pharmaceuticals, MAY 14, 2020, View Source [SID1234561095]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key findings from the study:

Overall survival (OS) 100% after a median follow-up time of 60 months
Median progression free survival (PFS) 34 months
No serious adverse events
The present study demonstrates that autologous NK cell-based immunotherapy is feasible and demonstrates clinical applicability with efficacy responses in an upfront autologous HSCT-setting in multiple myeloma (MM). The treatment strategy opens for usage of autologous NK cells in clinical settings where patients are not readily eligible for allogeneic NK cell-based treatments, including MRD and maintenance treatment in MM and other forms of malignancies.